View Future GrowthThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsBod Science 과거 순이익 실적과거 기준 점검 0/6Bod Science 의 수입은 연평균 -4.2%의 비율로 감소해 온 반면, Pharmaceuticals 산업은 연평균 5.8%의 비율로 증가했습니다. 매출은 연평균 20.2%의 비율로 증가해 왔습니다.핵심 정보-4.15%순이익 성장률14.60%주당순이익(EPS) 성장률Pharmaceuticals 산업 성장률31.22%매출 성장률20.19%자기자본이익률n/a순이익률-239.47%최근 순이익 업데이트30 Jun 2023최근 과거 실적 업데이트Reported Earnings • Aug 31Full year 2023 earnings released: AU$0.056 loss per share (vs AU$0.051 loss in FY 2022)Full year 2023 results: AU$0.056 loss per share (further deteriorated from AU$0.051 loss in FY 2022). Revenue: AU$3.64m (down 28% from FY 2022). Net loss: AU$7.95m (loss widened 47% from FY 2022). Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has fallen by 35% per year, which means it is performing significantly worse than earnings.Reported Earnings • Feb 25First half 2023 earnings released: AU$0.024 loss per share (vs AU$0.02 loss in 1H 2022)First half 2023 results: AU$0.024 loss per share (further deteriorated from AU$0.02 loss in 1H 2022). Revenue: AU$2.57m (down 25% from 1H 2022). Net loss: AU$3.17m (loss widened 46% from 1H 2022). Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 35% per year, which means it is significantly lagging earnings.Reported Earnings • Mar 01First half 2022 earnings: Revenues and EPS in line with analyst expectationsFirst half 2022 results: AU$0.02 loss per share (down from AU$0.014 loss in 1H 2021). Revenue: AU$3.44m (up 4.0% from 1H 2021). Net loss: AU$2.17m (loss widened 68% from 1H 2021). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has fallen by 28% per year, which means it is significantly lagging earnings.Reported Earnings • Aug 25Full year 2021 earnings released: AU$0.043 loss per share (vs AU$0.054 loss in FY 2020)The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2021 results: Revenue: AU$7.53m (up 27% from FY 2020). Net loss: AU$4.23m (loss narrowed 12% from FY 2020). Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has fallen by 23% per year, which means it is significantly lagging earnings.모든 업데이트 보기Recent updates공시 • Nov 10Bod Science Limited announced that it expects to receive AUD 2.05 million in fundingBod Science Limited announced a private placement of 68,333,333 fully paid ordinary shares at an issue price of AUD 0.03 per share for the gross proceeds of AUD 2,049,999.99 on November 8, 2023. The company will raise the funding in two tranches. The company will issue of 26,600,000 shares for the gross proceeds of AUD 80,000 in the first tranche and 41,700,000 shares for the gross proceeds of AUD 1,250,000 in second tranche. Tranche 2 includes the proposed issue of AUD 30,000 worth of shares to Jo Patterson subject to shareholder approval. Assuming Tranche 2 is approved, the transaction will involve the issue of 68.3 million shares. The transaction will include participation from new investor Antah Healthcare Group through a commitment of AUD 1,100,000 worth of shares. On completion of the transaction, it is expected that Antah Healthcare Group will hold a relevant interest of 14.9% of company's issued shares.공시 • Nov 09Bod Science Limited has filed a Follow-on Equity Offering in the amount of AUD 2.05 million.Bod Science Limited has filed a Follow-on Equity Offering in the amount of AUD 2.05 million. Security Name: Shares Security Type: Common Stock Securities Offered: 26,600,773 Price\Range: AUD 0.03 Security Name: Shares Security Type: Common Stock Securities Offered: 41,732,556 Price\Range: AUD 0.03 Transaction Features: Subsequent Direct ListingBoard Change • Nov 08No independent directorsThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 5 new directors. 7 experienced directors. No highly experienced directors. No independent directors (4 non-independent directors). Member of Medical Advisory Board Nick Burgess is the most experienced director on the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors.공시 • Oct 07Bod Science Limited has completed a Follow-on Equity Offering in the amount of AUD 1.93008 million.Bod Science Limited has completed a Follow-on Equity Offering in the amount of AUD 1.93008 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 19,751,000 Price\Range: AUD 0.08 Discount Per Security: AUD 0.0048 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 1,875,000 Price\Range: AUD 0.08 Discount Per Security: AUD 0.0048 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 2,500,000 Price\Range: AUD 0.08 Discount Per Security: AUD 0.0048 Transaction Features: Subsequent Direct Listing공시 • Oct 02Bod Science Limited, Annual General Meeting, Nov 27, 2023Bod Science Limited, Annual General Meeting, Nov 27, 2023. Agenda: To consider and approve the re-election of Directors.Reported Earnings • Aug 31Full year 2023 earnings released: AU$0.056 loss per share (vs AU$0.051 loss in FY 2022)Full year 2023 results: AU$0.056 loss per share (further deteriorated from AU$0.051 loss in FY 2022). Revenue: AU$3.64m (down 28% from FY 2022). Net loss: AU$7.95m (loss widened 47% from FY 2022). Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has fallen by 35% per year, which means it is performing significantly worse than earnings.New Risk • Aug 31New major risk - Negative shareholders equityThe company has negative equity. Total equity: -AU$703k This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$5.8m free cash flow). Share price has been highly volatile over the past 3 months (24% average weekly change). Negative equity (-AU$703k). Earnings have declined by 4.2% per year over the past 5 years. Shareholders have been substantially diluted in the past year (66% increase in shares outstanding). Market cap is less than US$10m (AU$12.3m market cap, or US$7.94m). Minor Risk Revenue is less than US$5m (AU$3.6m revenue, or US$2.4m).New Risk • Aug 26New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$4.2m free cash flow). Share price has been highly volatile over the past 3 months (24% average weekly change). Earnings have declined by 4.5% per year over the past 5 years. Shareholders have been substantially diluted in the past year (66% increase in shares outstanding). Market cap is less than US$10m (AU$14.0m market cap, or US$9.00m). Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Revenue is less than US$5m (AU$4.1m revenue, or US$2.6m).New Risk • Aug 13New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 63% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$4.2m free cash flow). Share price has been highly volatile over the past 3 months (23% average weekly change). Earnings have declined by 4.5% per year over the past 5 years. Shareholders have been substantially diluted in the past year (63% increase in shares outstanding). Market cap is less than US$10m (AU$12.8m market cap, or US$8.31m). Minor Risk Revenue is less than US$5m (AU$4.1m revenue, or US$2.7m).공시 • Aug 11Bod Australia Limited (ASX:BOD) completed the acquisition of Aqua Phase Ltd.Bod Australia Limited (ASX:BOD) entered into binding agreement to acquire Aqua Phase Ltd for £3 million on August 30, 2022. Bod will pay total consideration of £3 million with Initial payment of £1 million in cash to be paid upon satisfaction of conditions precedent relating to successful completion of upcoming manufacture, stability and bioavailability testing. Remaining consideration paid against further milestone achievements relating to pharmaceutical GMP manufacture and commercialization, with optionality for Bod to pay in cash or shares over a 12-36 month timeframe. The earnout payments are conditional upon ASX and shareholder's approval. As on March 7, 2023, Bod has successfully completed the stability testing of the Aqua Phase product format within the agreed time frame, along with the manufacture of a technical batch per the acquisition terms and timeframe. Due to third party delays involved in the testing and analyzing phase of the PK study, Bod Science has agreed with the Inventors to extend the date by which this test must be completed to June 30, 2023. As on March 28, 2023, Bod Science is pleased to report the PK study to confirm the bioavailability of Aqua Phase has been submitted for ethics approval, with approval expected within 2 weeks. Recruitment for study participants will commence immediately once ethics approval is received. The PK study will recruit 12 subjects and will continue for 4 weeks. Results are expected in June 2023. Bod Australia Limited (ASX:BOD) completed the acquisition of Aqua Phase Ltd on August 10, 2023.Board Change • Jun 01No independent directorsThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 5 new directors. 7 experienced directors. No highly experienced directors. No independent directors (4 non-independent directors). Member of Medical Advisory Board Nick Burgess is the most experienced director on the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors.Board Change • May 02No independent directorsThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 5 new directors. 7 experienced directors. No highly experienced directors. No independent directors (4 non-independent directors). Member of Medical Advisory Board Nick Burgess is the most experienced director on the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors.Reported Earnings • Feb 25First half 2023 earnings released: AU$0.024 loss per share (vs AU$0.02 loss in 1H 2022)First half 2023 results: AU$0.024 loss per share (further deteriorated from AU$0.02 loss in 1H 2022). Revenue: AU$2.57m (down 25% from 1H 2022). Net loss: AU$3.17m (loss widened 46% from 1H 2022). Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 35% per year, which means it is significantly lagging earnings.공시 • Jan 24Bod Science Limited Announces Company Secretary ChangesBod Science Limited announced the appointment of Carlie Hodges as Company Secretary upon the resignation of Stephen Kelly, effective 23 January 2023. Carlie is a practising corporate and commercial lawyer, holds a Graduate Diploma in Applied Corporate Governance and is a Fellow Member of the Governance Institute of Australia.Board Change • Dec 03Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 5 new directors. 7 experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). Member of Medical Advisory Board Nick Burgess is the most experienced director on the board, commencing their role in 2017. Independent Non-Executive Director Akash Bedi was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.Board Change • Oct 27Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 5 new directors. 7 experienced directors. No highly experienced directors. 1 independent director (4 non-independent directors). Member of Medical Advisory Board Nick Burgess is the most experienced director on the board, commencing their role in 2017. Independent Non-Executive Director Akash Bedi was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.Board Change • Oct 08Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 5 new directors. 7 experienced directors. No highly experienced directors. 1 independent director (4 non-independent directors). Member of Medical Advisory Board Nick Burgess is the most experienced director on the board, commencing their role in 2017. Independent Non-Executive Director Akash Bedi was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.Board Change • Aug 16Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 5 new directors. 7 experienced directors. No highly experienced directors. 1 independent director (4 non-independent directors). Member of Medical Advisory Board Nick Burgess is the most experienced director on the board, commencing their role in 2017. Independent Non-Executive Director Akash Bedi was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.Board Change • Jun 04Less than half of directors are independentThere are 6 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 6 new directors. 6 experienced directors. No highly experienced directors. 1 independent director (4 non-independent directors). Member of Medical Advisory Board Nick Burgess is the most experienced director on the board, commencing their role in 2017. Independent Non-Executive Director Akash Bedi was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.Board Change • May 03Less than half of directors are independentThere are 6 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 6 new directors. 6 experienced directors. No highly experienced directors. 2 independent directors (4 non-independent directors). Member of Medical Advisory Board Nick Burgess is the most experienced director on the board, commencing their role in 2017. Independent Non-Executive Chairman Mark Masterson was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.Reported Earnings • Mar 01First half 2022 earnings: Revenues and EPS in line with analyst expectationsFirst half 2022 results: AU$0.02 loss per share (down from AU$0.014 loss in 1H 2021). Revenue: AU$3.44m (up 4.0% from 1H 2021). Net loss: AU$2.17m (loss widened 68% from 1H 2021). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has fallen by 28% per year, which means it is significantly lagging earnings.Board Change • Feb 24High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 7 experienced directors. No highly experienced directors. Independent Non-Executive Director Simon O'Loughlin is the most experienced director on the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.Board Change • Jan 28High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 7 experienced directors. No highly experienced directors. Independent Non-Executive Director Simon O'Loughlin is the most experienced director on the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.Board Change • Dec 03High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 7 experienced directors. No highly experienced directors. Independent Non-Executive Director Simon O'Loughlin is the most experienced director on the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.Reported Earnings • Aug 25Full year 2021 earnings released: AU$0.043 loss per share (vs AU$0.054 loss in FY 2020)The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2021 results: Revenue: AU$7.53m (up 27% from FY 2020). Net loss: AU$4.23m (loss narrowed 12% from FY 2020). Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has fallen by 23% per year, which means it is significantly lagging earnings.Executive Departure • Apr 02Chief Financial Officer has left the companyOn the 29th of March, Charles Altshuler's tenure as Chief Financial Officer ended after 2.2 years in the role. We don't have any record of a personal shareholding under Charles' name. Charles is the only executive to leave the company over the last 12 months.Is New 90 Day High Low • Mar 10New 90-day low: AU$0.41The company is down 34% from its price of AU$0.62 on 09 December 2020. The Australian market is up 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Retail Distributors industry, which is flat over the same period.Is New 90 Day High Low • Feb 01New 90-day low: AU$0.42The company is down 13% from its price of AU$0.48 on 04 November 2020. The Australian market is up 13% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Retail Distributors industry, which is up 1.0% over the same period.Is New 90 Day High Low • Nov 24New 90-day high: AU$0.58The company is up 107% from its price of AU$0.28 on 26 August 2020. The Australian market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Retail Distributors industry, which is up 6.0% over the same period.Is New 90 Day High Low • Oct 15New 90-day high: AU$0.51The company is up 94% from its price of AU$0.26 on 17 July 2020. The Australian market is up 5.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Retail Distributors industry, which is up 41% over the same period.Is New 90 Day High Low • Sep 29New 90-day high: AU$0.40The company is up 46% from its price of AU$0.27 on 01 July 2020. The Australian market is up 3.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Retail Distributors industry, which is up 16% over the same period.매출 및 비용 세부 내역Bod Science가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이CHIA:BOD 매출, 비용 및 순이익 (AUD Millions)날짜매출순이익일반관리비연구개발비30 Jun 233-84331 Mar 234-74331 Dec 224-64230 Sep 225-65230 Jun 225-55231 Mar 226-55231 Dec 218-55230 Sep 218-55230 Jun 217-45231 Mar 217-44231 Dec 207-54230 Sep 207-54230 Jun 206-53231 Mar 204-64231 Dec 192-64130 Sep 192-75230 Jun 191-85231 Mar 191-64231 Dec 181-53230 Sep 181-43130 Jun 181-42131 Mar 181-32131 Dec 171-32030 Sep 171-32030 Jun 170-32031 Mar 170-32031 Dec 160-21030 Sep 160-11030 Jun 16000030 Jun 150000양질의 수익: BOD 은(는) 현재 수익성이 없습니다.이익 마진 증가: BOD는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: BOD은 수익성이 없으며 지난 5년 동안 손실이 연평균 4.2% 증가했습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 BOD의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: BOD은 수익성이 없어 지난 해 수익 성장률을 Pharmaceuticals 업계(-17.4%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: BOD의 부채가 자산을 초과하여 자본 수익률을 계산하기 어렵습니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YPharmaceuticals-biotech 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2024/02/20 11:28종가2023/11/23 00:00수익2023/06/30연간 수익2023/06/30데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Bod Science Limited는 1명의 분석가가 다루고 있습니다. 이 중 명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Alexander SmithPAC Partners Securities Pty. Ltd.
Reported Earnings • Aug 31Full year 2023 earnings released: AU$0.056 loss per share (vs AU$0.051 loss in FY 2022)Full year 2023 results: AU$0.056 loss per share (further deteriorated from AU$0.051 loss in FY 2022). Revenue: AU$3.64m (down 28% from FY 2022). Net loss: AU$7.95m (loss widened 47% from FY 2022). Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has fallen by 35% per year, which means it is performing significantly worse than earnings.
Reported Earnings • Feb 25First half 2023 earnings released: AU$0.024 loss per share (vs AU$0.02 loss in 1H 2022)First half 2023 results: AU$0.024 loss per share (further deteriorated from AU$0.02 loss in 1H 2022). Revenue: AU$2.57m (down 25% from 1H 2022). Net loss: AU$3.17m (loss widened 46% from 1H 2022). Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 35% per year, which means it is significantly lagging earnings.
Reported Earnings • Mar 01First half 2022 earnings: Revenues and EPS in line with analyst expectationsFirst half 2022 results: AU$0.02 loss per share (down from AU$0.014 loss in 1H 2021). Revenue: AU$3.44m (up 4.0% from 1H 2021). Net loss: AU$2.17m (loss widened 68% from 1H 2021). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has fallen by 28% per year, which means it is significantly lagging earnings.
Reported Earnings • Aug 25Full year 2021 earnings released: AU$0.043 loss per share (vs AU$0.054 loss in FY 2020)The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2021 results: Revenue: AU$7.53m (up 27% from FY 2020). Net loss: AU$4.23m (loss narrowed 12% from FY 2020). Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has fallen by 23% per year, which means it is significantly lagging earnings.
공시 • Nov 10Bod Science Limited announced that it expects to receive AUD 2.05 million in fundingBod Science Limited announced a private placement of 68,333,333 fully paid ordinary shares at an issue price of AUD 0.03 per share for the gross proceeds of AUD 2,049,999.99 on November 8, 2023. The company will raise the funding in two tranches. The company will issue of 26,600,000 shares for the gross proceeds of AUD 80,000 in the first tranche and 41,700,000 shares for the gross proceeds of AUD 1,250,000 in second tranche. Tranche 2 includes the proposed issue of AUD 30,000 worth of shares to Jo Patterson subject to shareholder approval. Assuming Tranche 2 is approved, the transaction will involve the issue of 68.3 million shares. The transaction will include participation from new investor Antah Healthcare Group through a commitment of AUD 1,100,000 worth of shares. On completion of the transaction, it is expected that Antah Healthcare Group will hold a relevant interest of 14.9% of company's issued shares.
공시 • Nov 09Bod Science Limited has filed a Follow-on Equity Offering in the amount of AUD 2.05 million.Bod Science Limited has filed a Follow-on Equity Offering in the amount of AUD 2.05 million. Security Name: Shares Security Type: Common Stock Securities Offered: 26,600,773 Price\Range: AUD 0.03 Security Name: Shares Security Type: Common Stock Securities Offered: 41,732,556 Price\Range: AUD 0.03 Transaction Features: Subsequent Direct Listing
Board Change • Nov 08No independent directorsThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 5 new directors. 7 experienced directors. No highly experienced directors. No independent directors (4 non-independent directors). Member of Medical Advisory Board Nick Burgess is the most experienced director on the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors.
공시 • Oct 07Bod Science Limited has completed a Follow-on Equity Offering in the amount of AUD 1.93008 million.Bod Science Limited has completed a Follow-on Equity Offering in the amount of AUD 1.93008 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 19,751,000 Price\Range: AUD 0.08 Discount Per Security: AUD 0.0048 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 1,875,000 Price\Range: AUD 0.08 Discount Per Security: AUD 0.0048 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 2,500,000 Price\Range: AUD 0.08 Discount Per Security: AUD 0.0048 Transaction Features: Subsequent Direct Listing
공시 • Oct 02Bod Science Limited, Annual General Meeting, Nov 27, 2023Bod Science Limited, Annual General Meeting, Nov 27, 2023. Agenda: To consider and approve the re-election of Directors.
Reported Earnings • Aug 31Full year 2023 earnings released: AU$0.056 loss per share (vs AU$0.051 loss in FY 2022)Full year 2023 results: AU$0.056 loss per share (further deteriorated from AU$0.051 loss in FY 2022). Revenue: AU$3.64m (down 28% from FY 2022). Net loss: AU$7.95m (loss widened 47% from FY 2022). Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has fallen by 35% per year, which means it is performing significantly worse than earnings.
New Risk • Aug 31New major risk - Negative shareholders equityThe company has negative equity. Total equity: -AU$703k This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$5.8m free cash flow). Share price has been highly volatile over the past 3 months (24% average weekly change). Negative equity (-AU$703k). Earnings have declined by 4.2% per year over the past 5 years. Shareholders have been substantially diluted in the past year (66% increase in shares outstanding). Market cap is less than US$10m (AU$12.3m market cap, or US$7.94m). Minor Risk Revenue is less than US$5m (AU$3.6m revenue, or US$2.4m).
New Risk • Aug 26New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$4.2m free cash flow). Share price has been highly volatile over the past 3 months (24% average weekly change). Earnings have declined by 4.5% per year over the past 5 years. Shareholders have been substantially diluted in the past year (66% increase in shares outstanding). Market cap is less than US$10m (AU$14.0m market cap, or US$9.00m). Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Revenue is less than US$5m (AU$4.1m revenue, or US$2.6m).
New Risk • Aug 13New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 63% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$4.2m free cash flow). Share price has been highly volatile over the past 3 months (23% average weekly change). Earnings have declined by 4.5% per year over the past 5 years. Shareholders have been substantially diluted in the past year (63% increase in shares outstanding). Market cap is less than US$10m (AU$12.8m market cap, or US$8.31m). Minor Risk Revenue is less than US$5m (AU$4.1m revenue, or US$2.7m).
공시 • Aug 11Bod Australia Limited (ASX:BOD) completed the acquisition of Aqua Phase Ltd.Bod Australia Limited (ASX:BOD) entered into binding agreement to acquire Aqua Phase Ltd for £3 million on August 30, 2022. Bod will pay total consideration of £3 million with Initial payment of £1 million in cash to be paid upon satisfaction of conditions precedent relating to successful completion of upcoming manufacture, stability and bioavailability testing. Remaining consideration paid against further milestone achievements relating to pharmaceutical GMP manufacture and commercialization, with optionality for Bod to pay in cash or shares over a 12-36 month timeframe. The earnout payments are conditional upon ASX and shareholder's approval. As on March 7, 2023, Bod has successfully completed the stability testing of the Aqua Phase product format within the agreed time frame, along with the manufacture of a technical batch per the acquisition terms and timeframe. Due to third party delays involved in the testing and analyzing phase of the PK study, Bod Science has agreed with the Inventors to extend the date by which this test must be completed to June 30, 2023. As on March 28, 2023, Bod Science is pleased to report the PK study to confirm the bioavailability of Aqua Phase has been submitted for ethics approval, with approval expected within 2 weeks. Recruitment for study participants will commence immediately once ethics approval is received. The PK study will recruit 12 subjects and will continue for 4 weeks. Results are expected in June 2023. Bod Australia Limited (ASX:BOD) completed the acquisition of Aqua Phase Ltd on August 10, 2023.
Board Change • Jun 01No independent directorsThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 5 new directors. 7 experienced directors. No highly experienced directors. No independent directors (4 non-independent directors). Member of Medical Advisory Board Nick Burgess is the most experienced director on the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors.
Board Change • May 02No independent directorsThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 5 new directors. 7 experienced directors. No highly experienced directors. No independent directors (4 non-independent directors). Member of Medical Advisory Board Nick Burgess is the most experienced director on the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors.
Reported Earnings • Feb 25First half 2023 earnings released: AU$0.024 loss per share (vs AU$0.02 loss in 1H 2022)First half 2023 results: AU$0.024 loss per share (further deteriorated from AU$0.02 loss in 1H 2022). Revenue: AU$2.57m (down 25% from 1H 2022). Net loss: AU$3.17m (loss widened 46% from 1H 2022). Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 35% per year, which means it is significantly lagging earnings.
공시 • Jan 24Bod Science Limited Announces Company Secretary ChangesBod Science Limited announced the appointment of Carlie Hodges as Company Secretary upon the resignation of Stephen Kelly, effective 23 January 2023. Carlie is a practising corporate and commercial lawyer, holds a Graduate Diploma in Applied Corporate Governance and is a Fellow Member of the Governance Institute of Australia.
Board Change • Dec 03Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 5 new directors. 7 experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). Member of Medical Advisory Board Nick Burgess is the most experienced director on the board, commencing their role in 2017. Independent Non-Executive Director Akash Bedi was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.
Board Change • Oct 27Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 5 new directors. 7 experienced directors. No highly experienced directors. 1 independent director (4 non-independent directors). Member of Medical Advisory Board Nick Burgess is the most experienced director on the board, commencing their role in 2017. Independent Non-Executive Director Akash Bedi was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.
Board Change • Oct 08Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 5 new directors. 7 experienced directors. No highly experienced directors. 1 independent director (4 non-independent directors). Member of Medical Advisory Board Nick Burgess is the most experienced director on the board, commencing their role in 2017. Independent Non-Executive Director Akash Bedi was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.
Board Change • Aug 16Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 5 new directors. 7 experienced directors. No highly experienced directors. 1 independent director (4 non-independent directors). Member of Medical Advisory Board Nick Burgess is the most experienced director on the board, commencing their role in 2017. Independent Non-Executive Director Akash Bedi was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.
Board Change • Jun 04Less than half of directors are independentThere are 6 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 6 new directors. 6 experienced directors. No highly experienced directors. 1 independent director (4 non-independent directors). Member of Medical Advisory Board Nick Burgess is the most experienced director on the board, commencing their role in 2017. Independent Non-Executive Director Akash Bedi was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.
Board Change • May 03Less than half of directors are independentThere are 6 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 6 new directors. 6 experienced directors. No highly experienced directors. 2 independent directors (4 non-independent directors). Member of Medical Advisory Board Nick Burgess is the most experienced director on the board, commencing their role in 2017. Independent Non-Executive Chairman Mark Masterson was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.
Reported Earnings • Mar 01First half 2022 earnings: Revenues and EPS in line with analyst expectationsFirst half 2022 results: AU$0.02 loss per share (down from AU$0.014 loss in 1H 2021). Revenue: AU$3.44m (up 4.0% from 1H 2021). Net loss: AU$2.17m (loss widened 68% from 1H 2021). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has fallen by 28% per year, which means it is significantly lagging earnings.
Board Change • Feb 24High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 7 experienced directors. No highly experienced directors. Independent Non-Executive Director Simon O'Loughlin is the most experienced director on the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
Board Change • Jan 28High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 7 experienced directors. No highly experienced directors. Independent Non-Executive Director Simon O'Loughlin is the most experienced director on the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
Board Change • Dec 03High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 7 experienced directors. No highly experienced directors. Independent Non-Executive Director Simon O'Loughlin is the most experienced director on the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
Reported Earnings • Aug 25Full year 2021 earnings released: AU$0.043 loss per share (vs AU$0.054 loss in FY 2020)The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2021 results: Revenue: AU$7.53m (up 27% from FY 2020). Net loss: AU$4.23m (loss narrowed 12% from FY 2020). Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has fallen by 23% per year, which means it is significantly lagging earnings.
Executive Departure • Apr 02Chief Financial Officer has left the companyOn the 29th of March, Charles Altshuler's tenure as Chief Financial Officer ended after 2.2 years in the role. We don't have any record of a personal shareholding under Charles' name. Charles is the only executive to leave the company over the last 12 months.
Is New 90 Day High Low • Mar 10New 90-day low: AU$0.41The company is down 34% from its price of AU$0.62 on 09 December 2020. The Australian market is up 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Retail Distributors industry, which is flat over the same period.
Is New 90 Day High Low • Feb 01New 90-day low: AU$0.42The company is down 13% from its price of AU$0.48 on 04 November 2020. The Australian market is up 13% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Retail Distributors industry, which is up 1.0% over the same period.
Is New 90 Day High Low • Nov 24New 90-day high: AU$0.58The company is up 107% from its price of AU$0.28 on 26 August 2020. The Australian market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Retail Distributors industry, which is up 6.0% over the same period.
Is New 90 Day High Low • Oct 15New 90-day high: AU$0.51The company is up 94% from its price of AU$0.26 on 17 July 2020. The Australian market is up 5.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Retail Distributors industry, which is up 41% over the same period.
Is New 90 Day High Low • Sep 29New 90-day high: AU$0.40The company is up 46% from its price of AU$0.27 on 01 July 2020. The Australian market is up 3.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Retail Distributors industry, which is up 16% over the same period.